FI61406C - Foerfarande foer framstaellning av ett oralt anvaendbart medelfoer profylax och terapi av gastro-enteritis hos primater vlket innehaoller antikroppar mot ncdv eller rotavirus - Google Patents
Foerfarande foer framstaellning av ett oralt anvaendbart medelfoer profylax och terapi av gastro-enteritis hos primater vlket innehaoller antikroppar mot ncdv eller rotavirus Download PDFInfo
- Publication number
- FI61406C FI61406C FI771143A FI771143A FI61406C FI 61406 C FI61406 C FI 61406C FI 771143 A FI771143 A FI 771143A FI 771143 A FI771143 A FI 771143A FI 61406 C FI61406 C FI 61406C
- Authority
- FI
- Finland
- Prior art keywords
- rotavirus
- ncdv
- weeks
- preparation
- och
- Prior art date
Links
- 241000702670 Rotavirus Species 0.000 title claims description 26
- 208000005577 Gastroenteritis Diseases 0.000 title claims description 8
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- 238000002360 preparation method Methods 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 15
- 210000000481 breast Anatomy 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 206010012735 Diarrhoea Diseases 0.000 claims description 7
- 244000309466 calf Species 0.000 claims description 7
- 241000283690 Bos taurus Species 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 230000006651 lactation Effects 0.000 claims description 3
- 210000002445 nipple Anatomy 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 2
- 240000006240 Linum usitatissimum Species 0.000 claims 1
- 241001506128 Bovine rotavirus strain NCDV/G6 Species 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 17
- 108010044091 Globulins Proteins 0.000 description 6
- 102000006395 Globulins Human genes 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 235000021277 colostrum Nutrition 0.000 description 5
- 210000003022 colostrum Anatomy 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 208000037951 infantile gastroenteritis Diseases 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108010074605 gamma-Globulins Proteins 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2616406A DE2616406B2 (de) | 1976-04-14 | 1976-04-14 | Mittel zur Prophylaxe und Therapie der Gastro-Enteritis |
| DE2616406 | 1976-04-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI771143A FI771143A (en18) | 1977-10-15 |
| FI61406B FI61406B (fi) | 1982-04-30 |
| FI61406C true FI61406C (fi) | 1982-08-10 |
Family
ID=5975367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI771143A FI61406C (fi) | 1976-04-14 | 1977-04-12 | Foerfarande foer framstaellning av ett oralt anvaendbart medelfoer profylax och terapi av gastro-enteritis hos primater vlket innehaoller antikroppar mot ncdv eller rotavirus |
Country Status (24)
| Country | Link |
|---|---|
| JP (1) | JPS52125621A (en18) |
| AR (1) | AR211891A1 (en18) |
| AT (1) | AT360644B (en18) |
| AU (1) | AU523590B2 (en18) |
| BE (1) | BE853603A (en18) |
| CA (1) | CA1092974A (en18) |
| CH (1) | CH634993A5 (en18) |
| DE (1) | DE2616406B2 (en18) |
| DK (1) | DK162777A (en18) |
| ES (1) | ES457602A1 (en18) |
| FI (1) | FI61406C (en18) |
| FR (1) | FR2347934A1 (en18) |
| GB (1) | GB1560344A (en18) |
| IE (1) | IE44814B1 (en18) |
| IL (1) | IL51863A (en18) |
| IT (1) | IT1075316B (en18) |
| LU (1) | LU77104A1 (en18) |
| NL (1) | NL7703879A (en18) |
| NO (1) | NO771289L (en18) |
| NZ (1) | NZ183842A (en18) |
| PT (1) | PT66433A (en18) |
| SE (1) | SE7704245L (en18) |
| YU (1) | YU96877A (en18) |
| ZA (1) | ZA772237B (en18) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341763A (en) | 1981-03-10 | 1982-07-27 | Smithkline-Rit | Methods of vaccinating humans against rotavirus infection |
| JPS58154513A (ja) * | 1982-03-09 | 1983-09-14 | Sendai Biseibutsu Kenkyusho | 予防及び治療薬 |
| JPH0813755B2 (ja) * | 1988-04-13 | 1996-02-14 | 太陽化学株式会社 | ウイルス性下痢症予防剤 |
| US6291228B1 (en) | 1988-08-03 | 2001-09-18 | Vericore Limited | Vaccine |
| AU5254790A (en) * | 1989-04-06 | 1990-10-11 | Chugai Seiyaku Kabushiki Kaisha | Process for preparing a therapeutic agent for rotavirus infection |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3304952A (en) * | 1965-03-15 | 1967-02-21 | William A Knapp Company | Vent control device |
-
1976
- 1976-04-14 DE DE2616406A patent/DE2616406B2/de not_active Withdrawn
-
1977
- 1977-04-06 ES ES457602A patent/ES457602A1/es not_active Expired
- 1977-04-07 NL NL7703879A patent/NL7703879A/xx not_active Application Discontinuation
- 1977-04-12 AR AR267176A patent/AR211891A1/es active
- 1977-04-12 FI FI771143A patent/FI61406C/fi not_active IP Right Cessation
- 1977-04-12 CH CH451477A patent/CH634993A5/de not_active IP Right Cessation
- 1977-04-12 YU YU00968/77A patent/YU96877A/xx unknown
- 1977-04-12 IL IL51863A patent/IL51863A/xx unknown
- 1977-04-12 IT IT22363/77A patent/IT1075316B/it active
- 1977-04-12 LU LU77104A patent/LU77104A1/xx unknown
- 1977-04-13 ZA ZA00772237A patent/ZA772237B/xx unknown
- 1977-04-13 IE IE768/77A patent/IE44814B1/en unknown
- 1977-04-13 NO NO771289A patent/NO771289L/no unknown
- 1977-04-13 NZ NZ183842A patent/NZ183842A/xx unknown
- 1977-04-13 SE SE7704245A patent/SE7704245L/ not_active Application Discontinuation
- 1977-04-13 PT PT66433A patent/PT66433A/pt unknown
- 1977-04-13 DK DK162777A patent/DK162777A/da not_active IP Right Cessation
- 1977-04-13 CA CA276,080A patent/CA1092974A/en not_active Expired
- 1977-04-13 AT AT257277A patent/AT360644B/de not_active IP Right Cessation
- 1977-04-13 AU AU24206/77A patent/AU523590B2/en not_active Expired
- 1977-04-14 GB GB15618/77A patent/GB1560344A/en not_active Expired
- 1977-04-14 JP JP4212877A patent/JPS52125621A/ja active Pending
- 1977-04-14 BE BE176722A patent/BE853603A/xx not_active IP Right Cessation
- 1977-04-14 FR FR7711217A patent/FR2347934A1/fr active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| ES457602A1 (es) | 1978-08-16 |
| CH634993A5 (en) | 1983-03-15 |
| GB1560344A (en) | 1980-02-06 |
| ZA772237B (en) | 1978-03-29 |
| YU96877A (en) | 1984-02-29 |
| NO771289L (no) | 1977-10-17 |
| IL51863A0 (en) | 1977-06-30 |
| IT1075316B (it) | 1985-04-22 |
| AT360644B (de) | 1981-01-26 |
| SE7704245L (sv) | 1977-10-15 |
| LU77104A1 (en18) | 1977-11-14 |
| DE2616406A1 (de) | 1977-10-20 |
| FI61406B (fi) | 1982-04-30 |
| FR2347934B1 (en18) | 1980-03-07 |
| AU523590B2 (en) | 1982-08-05 |
| PT66433A (de) | 1977-05-01 |
| AU2420677A (en) | 1978-10-19 |
| BE853603A (fr) | 1977-10-14 |
| IL51863A (en) | 1980-07-31 |
| DE2616406B2 (de) | 1980-08-07 |
| NZ183842A (en) | 1980-03-05 |
| NL7703879A (nl) | 1977-10-18 |
| FI771143A (en18) | 1977-10-15 |
| CA1092974A (en) | 1981-01-06 |
| FR2347934A1 (fr) | 1977-11-10 |
| AR211891A1 (es) | 1978-03-31 |
| ATA257277A (de) | 1980-06-15 |
| IE44814L (en) | 1977-10-14 |
| IE44814B1 (en) | 1982-04-07 |
| DK162777A (da) | 1977-10-15 |
| JPS52125621A (en) | 1977-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3911108A (en) | Process of producing bovine milk products containing specific antibodies | |
| JP2548115B2 (ja) | トリの抗体を用いた哺乳動物の受動免疫化 | |
| US7332165B2 (en) | Antibody production in farm animals | |
| US20080213263A1 (en) | Methods and compositions for treatment of immune dysfunction disorders | |
| EP0240344B1 (en) | Monoclonal antibodies and their use | |
| US20030103962A1 (en) | Methods and compositions for modulating the immune system of animals | |
| US20030099633A1 (en) | Methods and compositions for treatment of immune dysfunction disorders | |
| FI61406C (fi) | Foerfarande foer framstaellning av ett oralt anvaendbart medelfoer profylax och terapi av gastro-enteritis hos primater vlket innehaoller antikroppar mot ncdv eller rotavirus | |
| US20080019972A1 (en) | Method for Amplifying Therapeutic Vaccine Activity | |
| EP0839050B1 (en) | Method of enhancing cell mediated immune responses | |
| US6113916A (en) | Method of enhancing cell mediated immune responses | |
| Milner et al. | Pathogenesis of in utero infections with abortogenic and non-abortogenic alphaviruses in mice | |
| Hunsmann et al. | Active immunization with feline leukemia virus envelope glycoprotein suppresses growth of virus-induced feline sarcoma | |
| US4335105A (en) | Specific antigen vaccine for TGE in swine | |
| Odendaal et al. | The effect of passive immunization on active immunity against Clostridium perfringens type D in lambs | |
| ES2258483T3 (es) | Produccion de anticuerpos de secrecion mamaria en animales de granja. | |
| RU2264229C2 (ru) | Препарат секреторного иммуноглобулина а, обладающий противовирусным и антибактериальным действием | |
| RU2291709C1 (ru) | Способ иммунопрофилактики вирусных респираторных болезней телят | |
| Luoto et al. | Q Fever Studies in Southern California: XII. Aureomycin treatment of dairy cattle naturally infected with Coxiella burnetii | |
| Salmon | Humoral lactogenic immunity in the sow: basis and practice. | |
| CN116785428B (zh) | 一种复方抗hpv生物蛋白及其应用 | |
| Stěpánek et al. | Preparation of hyperimmune cow colostrum whey and its use in the protection of piglets against transmissible gastroenteritis | |
| RU2180238C1 (ru) | Биологический препарат для профилактики и лечения желудочно-кишечных и респираторных болезней телят | |
| AU2001236636B2 (en) | Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis | |
| AU597934B2 (en) | Treating pseudorabis virus infection in swine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: BEHRINGWERKE AKTIENGESELLSCHAFT |